The role of PKA in cancer is context-dependent: elevated PKA can promote oncogenic programs (Na et al., 2020; Chan et al., 2023; Shirani et al., 2024), whereas suppression of PKA signaling, including through overexpression of protein kinase inhibitor beta (PKIB), a competitive inhibitor that binds the PKA catalytic subunit, can also enhance tumor progression (Liu et al., 2025). This evidence concerns the gene PKIB and cancer.